Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies
Author:
- 1 July 2013
- journal article
- review article
- Published by Elsevier in Clinics in Dermatology
- Vol. 31 (4) , 432-437
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Cytokine profiles in localized scleroderma and relationship to clinical featuresCytokine, 2011
- Distinct Autoimmune Syndromes in MorpheaArchives of Dermatology, 2009
- Neurologic manifestations of localized sclerodermaNeurology, 2008
- UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-VBritish Journal of Dermatology, 2008
- Molecular Subsets in the Gene Expression Signatures of Scleroderma SkinPLOS ONE, 2008
- Period of remission after treatment with UVA‐1 in sclerodermic skin diseasesJournal of the European Academy of Dermatology and Venereology, 2008
- Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group databaseAnnals of the Rheumatic Diseases, 2007
- Ocular involvement in children with localised scleroderma: a multi-centre studyBritish Journal of Ophthalmology, 2007
- Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: Radiation port sclerodermaJournal of the American Academy of Dermatology, 1996
- Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized sclerodermaArchives of Dermatological Research, 1995